ThromboGenics NV, an integrated biopharmaceutical company focussed on developing and commercialising innovative ophthalmic medicines, has been awarded a €1.1 million research grant from the Flemish agency for Innovation by Science and Technology (IWT).
The grant will be used by Thrombogenics to fund the on-going research to further elucidate the pharmacological effects ocriplasmin is exerting in the back of the eye following intravitreal (IVT) injection.
Dr Patrik De Haes, chief executive officer, of ThromboGenics comments: “The award of this grant from IWT supports our commitment to gain further insight into JETREAs action in the vitreo-retinal interface. In conjunction with a growing body of real world and clinical trial data, we hope that the continual efforts at the preclinical research level will contribute to an improved awareness and acceptance of JETREA by physicians as a first in class pharmaceutical treatment for symptomatic VMA.”